| 000 | 01836 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517054135.0 | ||
| 264 | 0 | _c20170731 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a2151-4658 | ||
| 024 | 7 |
_a10.1002/acr.22722 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChester Wasko, Mary | |
| 245 | 0 | 0 |
_aPrednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. _h[electronic resource] |
| 260 |
_bArthritis care & research _c05 2016 |
||
| 300 |
_a706-10 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLong Term Adverse Effects _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aPropensity Score |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSulfasalazine _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDasgupta, Abhijit | |
| 700 | 1 | _aIlse Sears, Genevieve | |
| 700 | 1 | _aFries, James F | |
| 700 | 1 | _aWard, Michael M | |
| 773 | 0 |
_tArthritis care & research _gvol. 68 _gno. 5 _gp. 706-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/acr.22722 _zAvailable from publisher's website |
| 999 |
_c25304176 _d25304176 |
||